Loading…
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-88M | $-75M | $-67M | -24.5% | - | 22.0% |
| 2024 | $0M | $-70M | $-62M | $-53M | 37.7% | - | 30.5% |
| 2023 | $0M | $-50M | $-47M | $-45M | 41.1% | - | 17.5% |
| 2022 | $0M | $-41M | $-40M | $-38M | 57.5% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 41.37 | 50.33 | 70.56 | 88.98 |
| Research And Development | 34.60 | 40.63 | 57.29 | 60.26 |
| Selling General And Administration | 6.77 | 9.71 | 13.27 | 28.72 |
| Total Expenses | 41.37 | 50.33 | 70.56 | 88.98 |
| Operating Income | -41.37 | -50.33 | -70.56 | -88.98 |
| Total Operating Income As Reported | -41.37 | -50.33 | -70.56 | -88.98 |
| EBITDA | -41.25 | -49.75 | -69.89 | -88.34 |
| Normalized EBITDA | -41.25 | -49.75 | -69.89 | -88.34 |
| EBIT | -41.37 | -50.33 | -70.56 | -88.98 |
| Interest Income | 1.13 | 2.77 | 8.17 | 13.30 |
| Net Interest Income | 1.13 | 2.77 | 8.17 | 13.30 |
| Other Non Operating Income Expenses | - | 0.30 | 0.70 | 0.42 |
| Other Income Expense | - | 0.30 | 0.70 | 0.42 |
| Interest Income Non Operating | 1.13 | 2.77 | 8.17 | 13.30 |
| Net Non Operating Interest Income Expense | 1.13 | 2.77 | 8.17 | 13.30 |
| Pretax Income | -40.24 | -47.26 | -61.69 | -75.27 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | -40.24 | -47.26 | -61.69 | -75.27 |
| Net Income From Continuing And Discontinued Operation | -40.24 | -47.26 | -61.69 | -75.27 |
| Net Income From Continuing Operation Net Minority Interest | -40.24 | -47.26 | -61.69 | -75.27 |
| Net Income | -40.24 | -47.26 | -61.69 | -75.27 |
| Net Income Common Stockholders | -40.24 | -47.26 | -61.69 | -75.27 |
| Net Income Including Noncontrolling Interests | -40.24 | -47.26 | -61.69 | -75.27 |
| Normalized Income | -40.24 | -47.26 | -61.69 | -75.27 |
| Diluted NI Availto Com Stockholders | -40.24 | -47.26 | -61.69 | -75.27 |
| Basic Average Shares | 17.33 | 27.80 | 42.44 | - |
| Diluted Average Shares | 17.33 | 27.80 | 42.44 | - |
| Reconciled Depreciation | 0.12 | 0.58 | 0.67 | 0.65 |
| General And Administrative Expense | 6.77 | 9.71 | 13.27 | 28.72 |
| Other Gand A | 2.28 | 3.78 | 5.43 | 9.82 |
| Salaries And Wages | 4.48 | 5.92 | 7.84 | 18.90 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Sionna Therapeutics, Inc.this co. | SION | $1.7B | -22.66 | 5.56 | -24.5% | -18.75 |
| UFP Technologies, Inc. | UFPT | $1.7B | 25.43 | 4.10 | 16.1% | 16.79 |
| Biohaven Ltd. | BHVN | $1.7B | -2.32 | 32.96 | -1418.8% | -2.41 |
| Agios Pharmaceuticals, Inc. | AGIO | $1.7B | -4.15 | 1.44 | -34.6% | -3.56 |
| Taysha Gene Therapies, Inc. | TSHA | $1.7B |
| -15.53 |
| 6.85 |
| -44.1% |
| -13.39 |
| Novavax, Inc. | NVAX | $1.7B | 3.81 | -13.12 | -344.7% | 3.42 |
| Addus HomeCare Corporation | ADUS | $1.7B | 17.46 | 1.54 | 8.8% | 11.20 |
| GeneDx Holdings Corp. | WGS | $1.7B | -79.47 | 5.42 | -6.8% | 138.20 |
| Palvella Therapeutics, Inc. | PVLA | $1.6B | -39.48 | 58.85 | -149.1% | -44.28 |
| Peer Median | - | -3.24 | 4.76 | -39.4% | 0.51 | |